Related Experiment Video
Updated: Jul 19, 2026

A Soluble Tetrazolium-Based Reduction Assay to Evaluate the Effect of Antibodies on Candida tropicalis Biofilms
Published on: September 16, 2022
Anti-Saccharomyces cerevisiae antibody in intestinal Behçet's disease patients: relation to clinical course
Chang Hwan Choi1, Tae Il Kim, Byung Chang Kim
1Department of Internal Medicine, Institute of Gastroenterology, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.
Purpose:
This study was designed to assess anti-Saccharomyces cerevisiae antibody positive rate in Behçet's disease and intestinal Behçet's disease and to evaluate whether anti-Saccharomyces cerevisiae antibody expression is associated with clinical findings at diagnosis and clinical course of intestinal Behçet's disease.
Methods:
One hundred six patients with intestinal Behçet's disease, 30 patients with Behçet's disease, and 45 healthy control subjects were included. Anti-Saccharomyces cerevisiae antibody was detected by indirect immunofluorescence assay. According to anti-Saccharomyces cerevisiae antibody expression, the various parameters at diagnosis, cumulative relapse rates, and cumulative probabilities of operation were analyzed.
Results:
Anti-Saccharomyces cerevisiae antibody positive rate was 44.3 percent in intestinal Behçet's disease, 3.3 percent in Behçet's disease, and 8.8 percent in healthy control subjects. In patients with intestinal Behçet's disease, age, gender, distribution of Behçet's disease subtype, symptoms, laboratory tests, and colonoscopic findings at diagnosis were not different according to anti-Saccharomyces cerevisiae antibody expression. Cumulative probability of a first operation was significantly higher in anti-Saccharomyces cerevisiae antibody (+) intestinal Behçet's disease than in anti-Saccharomyces cerevisiae antibody (-) intestinal Behçet's disease: 44.8 and 17.2 percent at one year, and 53 and 24.3 percent at two years after diagnosis, respectively (P=0.006). The number of patients who underwent two or more operations was higher in anti-Saccharomyces cerevisiae antibody (+) intestinal Behçet's disease than in anti-Saccharomyces cerevisiae antibody (-) intestinal Behçet's disease (21.3 vs. 8.5 percent). The cumulative relapse rates were not different between the two groups.
Conclusions:
Anti-Saccharomyces cerevisiae antibody positive rate was 44.3 percent in intestinal Behçet's disease. Clinical findings at diagnosis and cumulative relapse rates of intestinal Behçet's disease were not found to be associated with anti-Saccharomyces cerevisiae antibody expression. However, patients with anti-Saccharomyces cerevisiae antibody (+) intestinal Behçet's disease were more likely to receive surgical treatment.
Related Concept Videos
Giardiasis
Inflammatory Bowel Disease IV: Clinical Manifestations
Amebiasis
Gastritis-II: Pathophysiology
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
Inflammatory Bowel Disease III: Crohn's Disease
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
